# US 2012/0269813 A1 · Polyclonal bispecific antibody compositions and method of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269813 A1
- Document ID: US20120269813A1
- Status: Published application
- Kind: A1
- Application number: 13/508,182
- Filed: 2010-11-05
- Published: 2012-10-25
- Earliest claimed: 2009-11-06
- Assignees: Wayne State University; Trans Target Inc.
- Inventors: Lawrence Lum; Manley Huang
- Web page: https://patentgrep.com/patent/US20120269813A1

## CPC

- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61K 39/42: viral
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/46: Viral antigens
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- C07K 16/06: from serum
- C07K 16/082: Hepadnaviridae (F), e.g. hepatitis B virus
- C07K 16/084: Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
- C07K 16/087: Herpes simplex virus
- C07K 16/089: {Cytomegalovirus}
- C07K 16/118: Hepatitis C virus; GB virus C [GBV-C]
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- A61K 2039/505: {comprising antibodies}
- A61K 2239/53: Liver
- C07K 2317/31: multispecific
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/998: Proteins not provided for elsewhere
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to compositions and methods for treating a host infected with a pathogen. The composition comprising a population of polyclonal bispecific binding molecules that can target and eliminate a host cell infected with the pathogen. Methods for activating and arming cytotoxic immune cells with the composition for use in treating a patient infected with a pathogen are also provided.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A method for treating a patient infected with a pathogen, the method comprising:
a) obtaining a sample of blood mononuclear cells comprising T-cells from a donor;
b) activating one or more of the T-cells ex vivo by stimulating the T-cells with soluble anti-CD3 antibody and culture of the T-cells in the presence of T-cell growth factors 10 IU/ml to 500 IU/ml IL-2, or in the presence of 25 to 100 ng/ml IL-7 and 25 to 100 ng/m1 IL-15;
c) arming the activated T-cells with a heterogeneous population of polyclonal bispecific binding molecules where each bispecific binding molecule comprises a first and a second antigen binding moiety,
wherein the first antigen binding moieties specifically bind to an antigen on the surface of a cytotoxic immune cell, said first antigen binding moieties being the same or different, and
wherein the second antigen binding moieties are a heterogeneous polyclonal population of antigen binding moieties against multiple different epitopes on one or more pathogenic antigens expressed or presented on the surface of a cell infected with the pathogen, said antigens being the same or different,
wherein the first antigen binding moiety is fused to the second antigen binding moiety to form the bispecific binding molecule, and
d) administering the armed T-cells to the patient in need thereof.

### Claim 30

(canceled)

### Claim 31 (depends on 29)

The method of claim 29, wherein the T-cell growth factors comprise IL-2, IL-7, and IL-15, present at a concentration of 10 IU/ml to 500 IU/ml for IL-2, 25-100 ng/ml for IL-7, and 25-100 ng/ml for IL-15.

### Claim 32 (depends on 29)

The method of claim 29, wherein the first binding moiety and the second binding moiety are antibodies or antigen binding fragments thereof

### Claim 33 (depends on 29)

The method of claim 29, wherein the first binding moiety is a monoclonal antibody or antigen binding fragment thereof and the second binding moiety comprises a population of polyclonal antibodies or an antigen binding fragments thereof

### Claim 34 (depends on 33)

The method of claim 33, wherein the population of polyclonal bispecific binding molecules comprises at least two different polyclonal antibodies as second antigen binding moieties with each antibody having a different antigen recognition specificity and being directed to different epitopes on the pathogen.

### Claim 35 (depends on 33)

The method of claim 33, wherein the population of polyclonal antibodies is derived from an immunoglobulin enriched serum fraction.

### Claim 36 (depends on 35)

The method of claim 35, wherein the IgG serum fraction is depleted of antibodies that recognize human leukocyte antigen (HLA) molecules.

### Claim 37 (depends on 33)

The method of claim 33, wherein the polyclonal antibody is derived from an autologous donor.

### Claim 38 (depends on 33)

The method of claim 33, wherein the polyclonal antibody is derived from an allogeneic donor or a pool of allogeneic donors.

### Claim 39 (depends on 29)

The method of claim 29, wherein the activated T-cell is derived from an autologous donor.

### Claim 40 (depends on 29)

The method of claim 29, wherein the activated T cell is derived from an allogeneic donor or a pool of allogeneic donors.

### Claim 41 (depends on 29)

The method of claim 29, wherein the first antigen binding moiety specifically binds to a molecule selected from the group consisting of CD2, CD3, CD4, CD5, CD8, CD11b, CD14, CD16a, CD28, CD45 and CD56.

### Claim 42 (depends on 41)

The method of claim 41, wherein the first binding moiety is an anti-CD3 antibody, or functional equivalent, or antigen binding fragment thereof.

### Claim 43 (depends on 42)

The method of claim 42, wherein the anti-CD3 antibody is OKT3 or a functional equivalent.

### Claim 44 (depends on 29)

The method of claim 29, wherein the arming dose of the population of polyclonal bispecific binding molecules is in the range of 0.001 ng to 100 ng per 106 activated T cells.

### Claim at position 18

45-47. (canceled)

### Claim 48 (depends on 29)

The method of claim 29, wherein the pathogen is selected from the group consisting of a virus, a bacterium, a fungus, and a parasite.

### Claim at position 20

49-51. (canceled)

### Claim 52 (depends on 29)

The method of claim 29, wherein the population of second antigen binding moieties is derived from CYTOGAM.

### Claim at position 22

53-54. (canceled)

### Claim 55 (depends on 29)

The method of claim 29, wherein the cytotoxic immune cell is selected from the group consisting of an activated T-cell, a natural killer (NK) cell, a dendritic cell, and a macrophage.
